MN-166 for ALS
MN-166 (ibudilast) is an experimental oral therapy that’s designed to reduce inflammation and protect nerve cells from damage in people with ALS. Developed by MediciNova, it’s expected to slow disease progression.
Search results for:
A Caregiver’s ALS Journey of Courage and Support
When ALS impacted RocÃo's husband Francisco, she knew the disease couldn't shake their greatest source of love and support—their family. Hear how they worked together to get Francisco the understanding and treatment he needed.
NP001 seen to extend survival, preserve lung function with ALS
Neuvivo’s investigational therapy NP001 (sodium chlorite), designed to dampen inflammation and restore immune system balance, extended survival in people with amyotrophic lateral sclerosis (ALS), according to an combined analysis of data, spanning up to 11 years, on patients who took part in either of two Phase 2…
NeuroSense moving to request early approval of PrimeC in Canada
NeuroSense Therapeutics has initiated the process of applying to Canada’s regulators for early marketing approval of PrimeC in treating amyotrophic lateral sclerosis (ALS), based on positive findings in a Phase 2b clinical trial. The application will be filed under Health Canada’s Notice of Compliance with Conditions policy, which could…
Home care model could offer more comfort for ALS patients: Pilot study
A home-based multidisciplinary care model for people living with amyotrophic lateral sclerosis (ALS) was found feasible, and was rated as highly satisfactory by both patients and caregivers, according to a pilot study conducted in Germany. The care model also helped patients avoid hospitalizations and remain at home during the…
My Treatment Journey From Mexico to the US
When Francisco was diagnosed with ALS he knew it would be an uphill battle, but what he didn't know was the journey it would take him on. Discover how Francisco found the courage to move forward in the face of ALS.
Dewpoint’s TDP-43-targeted ALS therapy gains further support
Dewpoint Therapeutics has won a second grant from Target ALS Foundation to advance preclinical studies of its experimental TDP-43-targeted therapy for amyotrophic lateral sclerosis (ALS). TDP-43 is a protein that often gets mislocalized within cells in ALS and forms into toxic clumps that contribute to neurodegeneration. Dewpoint’s…
ILB may slow ALS progression, per data from small clinical trial
Treatment with a high dose of ILB, an experimental injection therapy being developed by Tikomed, was well tolerated and appeared to slow the progression of amyotrophic lateral sclerosis (ALS) in a small clinical trial in the U.K. That’s according to data from the exploratory Phase 2 study…
Finding a New Purpose in the Face of ALS
Being diagnosed with ALS felt like a crushing blow to Craig. As a former band director who mentored students, he knew his life would change. Discover how Craig found his new purpose and community to inspire.
National Academies report aims to make ALS ‘livable’ in 10 years
The ALS Association is commending the National Academies of Sciences, Engineering, and Medicine for its “groundbreaking” and comprehensive report that maps a way toward making amyotrophic lateral sclerosis (ALS) a livable disease within a decade. The organization and ALS advocates played a key role in pushing for…